We’re starting to get a better idea of rheumatic irAE phenotypic clusters, which is the first step to better understanding and treatment - onward to collect more data, to get better detail! Many congratulations @ramos_casals! #EULAR2019 THU0649 @RheumNow https://t.co/TBYqb70Hsp

Updated treatment algorithm for various pathological subtypes of #Lupus Nephritis #EULAR2019 https://t.co/Uun2OQXJLl

In hand OA, both structural and inflammatory features are associated with pain sensitization (PPT = pain pressure threshold) #EULAR2019 OP0417 from Diakonhjemmet in Oslo @RheumNow https://t.co/97GwGGhH6Z

As we start to use MRI to treat nr-axSpA outside of the tertiary centers, we’ve got to ask - how good are the local readers compared to specialized ones? Caution and more community radiologist education required #EULAR2019 THU0359 from ASAS classification cohort @RheumNow https://t.co/7Qqp1z0chO

Is GCA seasonality present in the Southern Hemisphere (summer starts in December)? Maybe it’s when our pathologists are feeling summer-generous... small numbers but nice work from @winkler_gemma #EULAR2019 THU0323 @RheumNow https://t.co/v9iT965BAM

Congratulations to @EricMattesonMD on becoming a honorary member of the EULAR! Well deserved! #EULAR2019 https://t.co/yrjhfS2abB

First day in Numbers 🔢 #EULAR2019 👉🏻 More than 9⃣ million of impressions 👉🏻 Almost 4⃣ thousand Tweets 🐦 👉🏻 From 965 participants #RheumaTwitters Data from the Healthcare Hashtag Project - Symplur @symplur 🔗 https://t.co/Ib2D1WP09q https://t.co/GIncIijmFs

• #EULAR2019 Healthcare Social Media Analytics

Interstitial lung disease occurs in about half of all patients with systemic sclerosis; of these, about one-third will experience lung disease progression. "[Patients] needs to be screened [with high resolution CT] because a lung function test is not enough." #EULAR2019

GiACTA part 2 - the morning has arrived! Disappointment or hope for tocilizumab in GCA? I'll be live tweeting it as we go. Here's the abstract to start you off: https://t.co/qtH8E5rVrB #EULAR2019 OP0140 @RheumNow

• https://ard.bmj.com/content/78/Suppl_2/145.2.info

Positive results presented so yes, interest in molecules beyond JAKi. All good for people esp once patents finish! #EULAR2019 https://t.co/beW9GblqdF

• Lothar M. Kirsch 祁建德 on Twitter: "BTK inhibitor? There have been posters f…

Look at this list of Biosimilars to TNFis! How would you decide what to use? The cost to the payer & what might be imposed? #EULAR2019 https://t.co/DhshdumsXO

In GCA, concomitant PMR might separate out better prognosis phenotype. Mortality benefit in PMR-relevant OR 0.68 (0.58-0.80). Phenotypes important moving forward in therapeutic selection? #EULAR2019 THU0295 from U La Paz, Madrid @RheumNow https://t.co/4viMygbTcP

Good morning #EULAR2019 delegates. Come by and visit, meet the Editor! https://t.co/DagNuxGfDq

Cool data presented at #EULAR2019 by @CreakyJoints #ArthritisPower https://t.co/ZtFUsEiboR

• Healio Rheumatology on Twitter: "Nearly 60% of patients with #Arthritis re…

Think: Do you really need to repeat another ANA test?🤔 👉🏼Repeat Antinuclear #antibody testing after a negative result had limited utility in diagnosis of ANA associated rheumatological conditions Via Ai Li Yeo #EULAR2019 OP0020 @RheumNow #immunology #rheumedu https://t.co/eK7GTRn8Z7